Related Experiment Video

Updated: Dec 8, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.6K

Re: Enzalutamide and Survival in Non-metastatic Castration-resistant Prostate Cancer

Dominic Bagguley1, Sean Ong1, Nathan Lawrentschuk2

  • 1Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia; EJ Whitten Prostate Cancer Research Centre at Epworth, Melbourne, Australia.

European Urology
|September 20, 2020
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Serum and Plasma Copy Number Detection Using Real-time PCR
09:21

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

11.7K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.1K

Related Experiment Videos

Last Updated: Dec 8, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.6K
Serum and Plasma Copy Number Detection Using Real-time PCR
09:21

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

11.7K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.1K

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

559
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
559

Articles linked to this work by shared authors, journal, and citation graph.

Advancing Homologous Recombination Repair Mutation Testing in Prostate Cancer in Australia: Shifting the Focus to Hormone Sensitive Prostate Cancer.

Asia-Pacific journal of clinical oncology·2026

Management of De Novo miN1 Prostate Cancer in the PSMA-PET Era.

The Prostate·2026

Neoadjuvant therapies for clear cell renal cell carcinoma: review of current evidence and future applications.

World journal of urology·2026

Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma.

Nature communications·2026

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

European urology·2026

Radioligand Therapy for Prostate Cancer - A Clinical Consultation Guide.

European urology focus·2026

Pretreatment Tumor NECTIN4 RNA Expression Is Associated with First-line Enfortumab Vedotin Plus Pembrolizumab Efficacy in Metastatic Urothelial Cancer.

European urology·2026

Challenges of Using Circulating Tumour DNA: Insights from Advanced Prostate Cancer.

European urology·2026

Impact of Treatment Intensification with Abiraterone on Fracture-related Hospitalisation in Newly Diagnosed Prostate Cancer: A Secondary Analysis of Two Randomised Phase 3 Trials Within the STAMPEDE Trial Platform.

European urology·2026

Serum small extracellular vesicle-associated snoRNA panel adds diagnostic value to CEA and CYFRA21-1 for non-small cell lung cancer: an exploratory single-center study.

Frontiers in oncology·2026

The value of machine learning models in predicting lung metastasis in papillary thyroid carcinoma.

Frontiers in endocrinology·2026

Integrated bulk-single-cell transcriptomics identifies IL17RB as a candidate prognostic marker in colon cancer.

In silico pharmacology·2026

Development and temporal validation of preoperative and combined preoperative-pathological models for lymph node metastasis in early gastric cancer.

Frontiers in oncology·2026

Other primary malignancies are associated with inferior survival in multiple myeloma: a single-center matched retrospective cohort study.

Frontiers in oncology·2026

Externally validated explainable machine learning for postoperative recurrence prediction in early-stage NSCLC.

Frontiers in oncology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us